Pancreatitis is an inflammatory disease of the pancreas with significant morbidity and mortality, and accounts for more than 300,000 hospitalizations annually in the United States alone at a cost of over $2 billion. There is no targeted therapy for the disease. Its pathophysiological mechanism is not clear. Pancreatitis in both its acute and chronic forms, causes severe pain that is often managed with narcotics, among them morphine, which, like its derivatives has been shown to affect the immune system and inflammatory pathways in a number of other diseases. However, the effect of morphine or its derivatives on modulation of progression of pancreatitis has never been studied. Our preliminary data, using an experimentally induced acute pancreatitis model and treatment with morphine after the onset of the disease, clearly indicate a significant increase in severity of locl and systemic injury. This is an interesting finding, which, if true, could have significant implications on the clinical outcome. Based upon these observations, we hypothesized that morphine exacerbates pancreatitis and associated systemic injuries, and causes delay in regenerative response in both acute and chronic forms of the disease. This is an exciting hypothesis, which we propose to test using three specific aims.
The FIRST aim of our study will evaluate the effect of morphine and other opioids on injury and regeneration using three different experimental models of acute pancreatitis. This, while confirming previous observations, will also show whether the morphine effects are disease-specific rather than model- specific. In this aim, we will also confirm if the observed effect of morphine operates via the mu-opioid receptor. The proposed studies in the SECOND aim will look into the mechanism of morphine-mediated worsening of pancreatitis and the role of gut permeability using TLR2 and TL4 knockout mice. In this, based upon our preliminary data, we will specifically study how altered macrophage influx, switching of status and function affect pancreatic injury and its resolution. In the THIRD aim, we will evaluate the effect of morphine on chronic pancreatitis using two different experimental models with different mechanisms of action. We will investigate whether use of morphine promotes conversion of the recurrent acute form of the disease to the chronic form. Further, we will also study if morphine use to alleviate pain in chronic pancreatitis actually worsens the tissue damage, enhances fibrosis and hastens the destruction of the organ. If our results bear out in these studies, this would suggest that a seemingly benign supportive intervention like morphine is actually worsening the course of acute and chronic pancreatitis. The proposed studies have immediate clinical implication and have the potential to change the paradigm of treatment of acute and chronic pancreatitis.
Pancreatitis, an inflammatory disease of pancreas leads to more than 300,000 admissions to hospitals in the United States alone. As the disease is associated with severe pain in both its acute and chronic form, pain management with opioids is one of the main treatment modalities. Morphine, one of the most commonly used opioid, affects immune system of the patient and results in increased inflammation. However, the effect of morphine or its derivatives on progression of pancreatitis has never been studied. Data from our group indicates that use of morphine in management of pancreatitis may actually result in worsening of the disease at both local and systemic levels. This is an interesting finding, which i true could have significant implications on the clinical outcome. Based upon these observations, we hypothesized that morphine exacerbates pancreatitis and associated systemic injuries, causes delay in regenerative response in both acute and chronic form of the disease. In the current proposal, we will test this hypothesis by using multiple animal models of this disease. We will further study the mechanism by which morphine may be deteriorating pancreatitis and study the effect of morphine administration on tissue regeneration following injury. Finally, we will also study if morphine use to alleviate pain in chronic pancreatitis actually worsen the tissu damage, enhance fibrosis and hastens the destruction of the organ. Successful completion of the proposed study will establish if administration of morphine is indeed resulting in worsening of the disease and will have the potential of changing the paradigm of treatment of acute and chronic pancreatitis.
|Sethi, Vrishketan; Giri, Bhuwan; Saluja, Ashok et al. (2017) Insights into the Pathogenesis of Pancreatic Cystic Neoplasms. Dig Dis Sci 62:1778-1786|
|Talukdar, Rupjyoti; Sareen, Archana; Zhu, Hongyan et al. (2016) Release of Cathepsin B in Cytosol Causes Cell Death in Acute Pancreatitis. Gastroenterology 151:747-758.e5|
|Banerjee, Sulagna; Saluja, Ashok (2015) Minnelide, a novel drug for pancreatic and liver cancer. Pancreatology 15:S39-43|
|Sah, Raghuwansh P; Garg, Sushil K; Dixit, Ajay K et al. (2014) Endoplasmic reticulum stress is chronically activated in chronic pancreatitis. J Biol Chem 289:27551-61|
|Pasca di Magliano, Marina; Forsmark, Christopher; Freedman, Steven et al. (2013) Advances in acute and chronic pancreatitis: from development to inflammation and repair. Gastroenterology 144:e1-4|
|Sah, Raghuwansh P; Dawra, Rajinder K; Saluja, Ashok K (2013) New insights into the pathogenesis of pancreatitis. Curr Opin Gastroenterol 29:523-30|
|Sah, Raghuwansh P; Dudeja, Vikas; Dawra, Rajinder K et al. (2013) Cerulein-induced chronic pancreatitis does not require intra-acinar activation of trypsinogen in mice. Gastroenterology 144:1076-1085.e2|
|Sah, Raghuwansh P; Garg, Pramod; Saluja, Ashok K (2012) Pathogenic mechanisms of acute pancreatitis. Curr Opin Gastroenterol 28:507-15|
|Sah, Raghuwansh P; Saluja, Ashok (2011) Molecular mechanisms of pancreatic injury. Curr Opin Gastroenterol 27:444-51|
|Phillips, P A; Sangwan, V; Borja-Cacho, D et al. (2011) Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett 308:181-8|
Showing the most recent 10 out of 32 publications